Intellia Therapeutics' (NTLA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA - Free Report) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

NTLA has been the subject of a number of other research reports. Chardan Capital reiterated a "buy" rating and issued a $68.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 9th. The Goldman Sachs Group restated a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research note on Friday, February 28th. Wells Fargo & Company lowered their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Guggenheim lowered their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Finally, Truist Financial reduced their target price on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Two analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $34.95.

Intellia Therapeutics Trading Up 0.2%

Shares of NASDAQ:NTLA traded up $0.02 on Monday, hitting $9.60. The company had a trading volume of 5,758,175 shares, compared to its average volume of 2,883,590. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $28.18. The business has a 50 day moving average of $8.24 and a 200 day moving average of $9.74. The company has a market cap of $994.37 million, a PE ratio of -1.84 and a beta of 2.14.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The firm's revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.12) earnings per share. As a group, equities analysts predict that Intellia Therapeutics will post -5.07 EPS for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth $25,000. Sterling Capital Management LLC boosted its position in shares of Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after buying an additional 2,867 shares during the period. Whipplewood Advisors LLC acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth $40,000. Resona Asset Management Co. Ltd. acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth $43,000. Finally, Jones Financial Companies Lllp boosted its position in shares of Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after buying an additional 2,280 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.